GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more
GenSight Biologics S.A (GSGTF) - Total Assets
Latest total assets as of June 2025: $7.35 Million USD
Based on the latest financial reports, GenSight Biologics S.A (GSGTF) holds total assets worth $7.35 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GenSight Biologics S.A - Total Assets Trend (2012–2024)
This chart illustrates how GenSight Biologics S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GenSight Biologics S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
GenSight Biologics S.A's total assets of $7.35 Million consist of 49.7% current assets and 50.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.9% |
| Accounts Receivable | $1.00K | 0.0% |
| Inventory | $-1.00K | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $57.00K | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how GenSight Biologics S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GenSight Biologics S.A's current assets represent 49.7% of total assets in 2024, a decrease from 88.6% in 2012.
- Cash Position: Cash and equivalents constituted 22.9% of total assets in 2024, down from 31.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 0.5% of total assets.
GenSight Biologics S.A Competitors by Total Assets
Key competitors of GenSight Biologics S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
GenSight Biologics S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - GenSight Biologics S.A generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GenSight Biologics S.A is currently not profitable relative to its asset base.
GenSight Biologics S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.77 | 1.73 |
| Quick Ratio | 0.11 | 0.77 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-22.91 Million | $ -3.85 Million | $ 9.69 Million |
GenSight Biologics S.A - Advanced Valuation Insights
This section examines the relationship between GenSight Biologics S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.46 |
| Latest Market Cap to Assets Ratio | 1.93 |
| Asset Growth Rate (YoY) | 17.8% |
| Total Assets | $10.76 Million |
| Market Capitalization | $20.78 Million USD |
Valuation Analysis
Above Book Valuation: The market values GenSight Biologics S.A's assets above their book value (1.93 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: GenSight Biologics S.A's assets grew by 17.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GenSight Biologics S.A (2012–2024)
The table below shows the annual total assets of GenSight Biologics S.A from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.76 Million | +17.78% |
| 2023-12-31 | $9.13 Million | -64.80% |
| 2022-12-31 | $25.94 Million | -54.21% |
| 2021-12-31 | $56.65 Million | +19.61% |
| 2020-12-31 | $47.36 Million | +45.80% |
| 2019-12-31 | $32.48 Million | -12.16% |
| 2018-12-31 | $36.98 Million | -40.56% |
| 2017-12-31 | $62.21 Million | +5.03% |
| 2016-12-31 | $59.23 Million | +63.12% |
| 2015-12-31 | $36.31 Million | +145.07% |
| 2014-12-31 | $14.82 Million | -21.49% |
| 2013-12-31 | $18.87 Million | +31033.60% |
| 2012-12-31 | $60.62K | -- |